Xiaosi Gu, PhD
- ASSOCIATE PROFESSOR | Psychiatry
- ASSOCIATE PROFESSOR | Neuroscience
Research Topics:
Addiction, Brain Imaging, Computational Neuroscience, Neural Networks, Neuroscience, PsychiatryDr. Xiaosi Gu currently Associate Professor in Psychiatry and Neuroscience, and Director of Center for Computational Psychiatry at Mount Sinai. After receiving a dual degree in Psychology and Economics from Peking University in Beijing, Dr. Gu moved to New York City to pursue a Ph.D. in Neuroscience at the Icahn School of Medicine at Mount Sinai. Dr. Gu then completed her postdoctoral training in computational psychiatry at Virginia Tech and the Wellcome Trust Centre for Neuroimaging, University College London (UCL). During her time in London, she also set up and has since been directing the world’s first computational psychiatry course at UCL. Before joining Sinai, Dr. Gu previously held faculty positions at the University of Texas, Dallas and UT Southwestern Medical Center.
Dr. Xiaosi Gu is one of the foremost researchers in the area of computational psychiatry. Her research examines the neural and computational mechanisms underlying human beliefs, emotions, decision making, and social interaction in both health and disease, through a synthesis of neuroscience, cognitive science, and behavioral economics. Her lab has also recently started to use human intracranial recording techniques to examine the neuroelectricl and neurochemical substrates of high order cognition.
Currently on-going research projects in Dr. Gu's lab include: 1) drug and food craving; 2) impulsivity and compulsitivty; 3) social deficits across health and disorders, including autism spectrum disorders, personality disorders, and misophonia; 4) the neurochemical substrates of social interactions.
PubMed: https://www.ncbi.nlm.nih.gov/myncbi/1tI7lobE31ak6/bibliography/public/
Laboratory Website: https://www.neurocpu.org
Multi-Disciplinary Training Areas
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Neuroscience [NEU]Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Gu did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.